Research programme: respiratory/autoimmune/inflammation therapy - AstraZeneca
Alternative Names: anti-C5 monoclonal antibodies - AstraZeneca; anti-C5/C5a monoclonal antibodies - AstraZeneca; anti-C5a monoclonal antibodies - AstraZeneca; anti-complement-5 monoclonal antibodies - AstraZeneca; anti-complement-5a monoclonal antibodies - AstraZenecaLatest Information Update: 06 Aug 2021
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors; Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Respiration disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (Parenteral)